The DOI matches its Crossref record.
Resistance of yeasts to azole-derivative antifungals
Abstract
There are relatively few antifungal agents available for the treatment of systemic mycoses. The incidence of these infections, particularly among the immunocompromised, has increased significantly in recent years. Amphotericin B, flucytosine and the azole-derivatives--fluconazole, itraconazole and ketoconazole--are the only drugs of value in the treatment of systemic yeast infections currently available. To date resistance among individual yeast species or strains has only been a serious problem with flucytosine. However, resistance among Candida spp. to orally administered azole-derivatives has been observed. The frequency with which resistance has been described in clinical practice among yeasts differs considerably between the three azole antifungal agents. Fluconazole has been implicated in emergent resistance more frequently than ketoconazole, and ketoconazole more often than itraconazole. It must be a matter for concern that, by analogy with the known emergence of antibiotic-resistance among bacteria, that the widespread use of a drug inactive against a particular species may lead to an increased incidence of such infections. An international epidemiological survey is required to establish the extent and degree of resistance to the azole antifungals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815
Oral Azole Drugs as Systemic Antifungal Therapy
Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300407 · Cited by 596
Antifungal agents: chemotherapeutic targets and immunologic strategies
Georgopapadakou, N. H., & Walsh, T. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.279 · Cited by 498
Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants
Kaufman, D., & Fairchild, K. D. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.3.638-680.2004 · Cited by 435
The Ins and Outs of DNA Fingerprinting the Infectious Fungi
Soll, D. R. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.332 · Cited by 346
Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance
Albertson, G. D., Niimi, M., Cannon, R. D., & Jenkinson, H. F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.12.2835 · Cited by 260
Molecular mechanisms of drug resistance in fungi
Vanden Bossche, H., Marichal, P., & Odds, F. C. (1994) · Trends in Microbiology · doi:10.1016/0966-842x(94)90618-1 · Cited by 254
Self-citationAl-Tel, T. H., Al-Qawasmeh, R. A., & Zaarour, R. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.051 · Cited by 252
Molecular biological characterization of an azole-resistant Candida glabrata isolate
Marichal, P., Vanden Bossche, H., Odds, F. C., Nobels, G., Warnock, D. W., Timmerman, V, Van Broeckhoven, C., Fay, S., & Mose-Larsen, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2229 · Cited by 210
Self-citationExperimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750
Barchiesi, F., Calabrese, D., Sanglard, D., Falconi Di Francesco, L., Caselli, F., Giannini, D., Giacometti, A., Gavaudan, S., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1578-1584.2000 · Cited by 145
“tropicalis has been reported to be often resistant to FLC (14, 21).”
BackgroundWakabayashi, H., Abe, S., Okutomi, T., Tansho, S., Kawase, K., & Yamaguchi, H. (1996) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1996.tb01147.x · Cited by 116
White, T., Pfaller, M., Rinaldi, M., Smith, J., & Redding, S. (1997) · Oral Diseases · doi:10.1111/j.1601-0825.1997.tb00336.x · Cited by 107
Scott, E. M., Tariq, V. N., & McCrory, R. M. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2610 · Cited by 69
“In addition, while the azoles have been used successfully for the treatment of Candida infections, numerous reports of treatment failures are now appearing in the literature (6).”
BackgroundAntifungal agents in neonatal systemic candidiasis
van den Anker, J. N., van Popele, N. M., & Sauer, P. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1391 · Cited by 46
Synergy of Nitric Oxide and Azoles against Candida Species In Vitro
McElhaney-Feser, G. E., Raulli, R. E., & Cihlar, R. L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2342 · Cited by 41
“However, as noted elsewhere, the precise definition of relative resistance levels remains unresolved, due in part to technical difficulties in the reproducibility of susceptibility testing (21, 31).”
BackgroundResult
Metadata
- Authors
- Odds, F. C.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 1993
- Volume
- 31
- Issue
- 4
- Pages
- 463-471
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2140536918
- Cited by
- 218
- References
- 0
- FWCI
- 19.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.